Nano Science and Technology Institute

NanoViricides to Present Influenza Study Results at the TechConnect World 2011 Conference in Boston

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") announced today that it has been invited to present its anti-influenza drug development studies at the TechConnect World 2011 Conferences and Expo.

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") announced today that it has been invited to present its anti-influenza drug development studies at the TechConnect World 2011 Conferences and Expo. The Conferences and Expo are being held June 13-16 at the Hynes Convention Center in Boston, MA (http://www.techconnectworld.com/World2011/).

“Bio Nano Materials: Novel bio nano materials and applications”

Dr. Anil R. Diwan, President and Chairman of the Company, will present a talk entitled “Nanoviricides® as Anti-Influenza Agents” at this Conference. This oral presentation is scheduled for 11:20 am on June 16, in the session entitled “Bio Nano Materials: Novel bio nano materials and applications” (http://www.techconnectworld.com/World2011/thursday.html).

The Company has completed several anti-influenza animal efficacy studies to date. The Company has improved its FluCide™ candidates successfully with each study.

In the most recent study, the Company has reported that post-infection treatment with its optimized FluCide™ drug candidates achieved 1,000-fold reduction in the levels of infectious virus in the lungs of animals with a lethal influenza virus infection. Of great clinical significance is the fact that 2 of the optimized FluCide™ drug candidates maintained this greatly reduced lung viral load throughout the duration of this 21 day study. Thus, treatment with FluCide drug candidates appeared to protect against the complete cycle of infection, virus expansion and spread of infection in the lungs that follows the initial virus infection. These findings corroborate the previously reported findings of both increased animal survival and protection of the lungs from influenza virus tissue damage in FluCide-treated animals in this H1N1 influenza study.

In contrast, Oseltamivir (Tamiflu® Roche) demonstrated very limited efficacy in the same study. Thus, animals treated with oseltamivir showed less than a 2-fold reduction in lung viral load at the same time point where FluCide candidates demonstrated a greater than 1,000-fold reduction (i.e. at 4 days post infection). This indicated a 500-fold greater reduction in viral load by FluCide drug candidates over Oseltamivir. In addition, in the animals treated with Oseltamivir (Tamiflu®, Roche) the lung viral load increased at 7 days to the same level as that found in the infected, untreated control animals shortly before their death. In contrast, the lung viral load in the FluCide candidate treated animals remained at the low levels attained at 4 days for the entire 21 days study duration for two of the candidates.

The Company has previously reported that the same optimized FluCide™ nanoviricide drug candidates achieved significantly increased survival (20.2 to 22.2 days) and greater than 95% reduction in lung inflammation and necrosis in this study. In contrast, animals treated with Oseltamivir showed a mean survival of just 8.3 days and only a 50% reduction in lung inflammation and necrosis.

The Company will present the data and discuss their significance at this meeting.

The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated directly into the lungs of mice. The same quantity of virus infection was repeated at 22 hrs. This influenza model was designed to be uniformly fatal in 100% of the infected, untreated animals within 5 days after infection. Treatment with the FluCide candidates and Oseltamivir commenced 24 hours after the first viral infection. The duration of the study was 21 days.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.


 
© 2014 Nano Science and Technology Institute. All Rights Reserved.
Terms of Use | Privacy Policy | Contact Us | Site Map